Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;33(4):407-10.
doi: 10.5152/balkanmedj.2016.150610. Epub 2016 Jul 1.

KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer

Hilmi Kodaz  1 , Ebru Taştekin  2 , Bülent Erdoğan  1 , İlhan Hacıbekiroğlu  1 , Hilmi Tozkır  3 , Hakan Gürkan  3 , Esma Türkmen  1 , Bora Demirkan  3 , Sernaz Uzunoğlu  1 , İrfan Çiçin  1
Affiliations

KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer

Hilmi Kodaz et al. Balkan Med J. 2016 Jul.

Abstract

Background: Lung cancer is one of the most lethal cancers. It is mainly classified into 2 groups: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Extrapulmonary small cell carcinomas (EPSCC) are very rare. The Ras oncogene controls most of the cellular functions in the cell. Overall, 21.6% of human cancers contain a Kirsten Ras (KRAS) mutation. SCLC and EPSCC have several similar features but their clinical course is different.

Aims: We investigated the KRAS mutation status in SCLC and EPSCC.

Study design: Mutation research.

Methods: Thirty-seven SCLC and 15 EPSCC patients were included in the study. The pathological diagnoses were confirmed by a second pathologist. KRAS analysis was performed in our medical genetic department. DNA isolation was performed with primary tumor tissue using the QIAamp DNA FFPE Tissue kit (Qiagen; Hilden, Germany) in all patients. The therascreen KRAS Pyro Kit 24 V1 (Qiagen; Hilden, Germany) was used for KRAS analyses.

Results: Thirty-four (91.9%) of the SCLC patients were male, while 11 (73.3%) of the EPSCC l patients were female. SCLC was more common in males, and EPSCC in females (p=0.001). A KRAS mutation was found in 6 (16.2%) if SCLC patients. The most common mutation was Q61R (CAA>CGA). Among the 15 EPSCC patients, 2 had a KRAS mutation (13.3%). When KRAS mutant and wild type patients were compared in the SCLC group, no difference was found for overall survival (p=0.6).

Conclusion: In previous studies, the incidence of KRAS mutation in SCLC was 1-3%; however, it was 16.2% in our study. Therefore, there may be ethnic and geographical differences in the KRAS mutations of SCLC. As a result, KRAS mutation should not be excluded in SCLC.

Keywords: KRAS mutation; Small cell lung cancer; extrapulmonary small cell carcinoma.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
SCLC overall survivall
See this image and copyright information in PMC

References

    1. Siegel RL, Sahar L, Portier KM, Ward EM, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. http://dx.doi.org/10.3322/caac.21314. - DOI - PubMed
    1. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46. http://dx.doi.org/10.1016/S1470-2045(11)70393-X. - DOI - PubMed
    1. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. N Engl J Med. 2010;363:1693–703. http://dx.doi.org/10.1056/NEJMoa1006448. - DOI - PMC - PubMed
    1. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 1999;17:1794–801. - PubMed
    1. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83:355–67. http://dx.doi.org/10.4065/83.3.355. - DOI - PubMed

LinkOut - more resources